Raloxifene to treat inflammatory processes by COVID-19

This study aims to characterise the pharmacological profile of raloxifene against bradykinin receptors to treat inflammatory processes due to COVID-19

Keywords: nonpeptide bradykinin partial agonist; drug repurposing; Covid-19 therapies; raloxifene


Functional efficacy study of raloxifene on CHO cells stably transfected with the B2 receptor (N=2). (a) Study of the agonistic effect of the compound compared to bradykinin; (b) study of the efficacy of the compound antagonizing bradykinin.

The good results of the different lines of research on raloxifene make it very likely that the compound is a good candidate as a drug against COVID-19.

Juan Jesús Pérez

Description of the Study:

  • Title: Discovery of a Bradykinin B2 Partial Agonist Profile of Raloxifene in a Drug Repurposing Campaign.
  • Principal Investigators: Patricia Gomez-Gutierrez and Juan J. Perez.
  • Design: Through virtual drug screening they have searched for drugs capable of downregulating bradykinin signalling and have found raloxifene. Once the compound was identified in silico, a sample was sent to an external laboratory for in vitro characterisation to corroborate its new pharmacological profile.
  • Methods: Drug screening has been carried out using computer-aided drug design methodologies.

Objectives of the Study:

Principal Objective: To characterize the pharmacological profile of raloxifene towards the bradykinin receptors.

More about this Study:

Scientific Context: Approximately 20% of COVID-19 patients present a severe clinical picture and require intensive care. These individuals develop pneumonia of varying degrees that can progress to more severe stages and lead to organ dysfunction. In these severe cases of the disease, elevated levels of various pro-inflammatory molecules, a phenomenon known as cytokine storm, are observed. Recently, it has been found that an inflammatory mediator called bradykinin may be the precursor of this inflammatory process that affects the most severe patients and can be life-threatening.


Other Studies about Pharmacology:

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la progestérone dans le traitement de COVID-19 chez les hommes hospitalisés.

Flower 729514 1920

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.


CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.

Vaccination In People With Long COVID

This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID.

Antibiotic prescription during the COVID-19 pandemic

Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.

Antihistamines and azithromycin as a treatment for COVID-19

This study suggests that primary care diagnosis and treatment with antihistamines, plus azithromycin in selected cases, may treat COVID-19 and prevent progression to severe disease in elderly patients.

Immunomodulatory Treatment In Patients With Severe Pneumonia COVID-19

Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this disease.

Real-life Use Of Remdesivir In Hospitalized Patients With COVID-19

This study aims to evaluate in clinical practice the efficacy and safety of remdesivir in patients admitted for COVID-19.

Prevention With Calcifediol Of Respiratory Problems Caused By COVID-19

This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.